NCT04390945

Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: The First Affiliated Hospital of Henan University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

China is a country with a large incidence of esophageal cancer. The prevalence and mortality rate of esophageal cancer in China ranks fifth in the world. However, due to China's huge population base, new patients with esophageal cancer and deaths account for about 55% of the world. This study aimed to explore the efficacy and safety of Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer.

Detailed description

This is an open clinical study to evaluate the efficacy and safety of Camrelizumab combined with Concurrent Radiotherapy and Chemotherapy in the treatment of locally recurrent esophageal cancer. Objective to study patients with local recurrence of esophageal cancer after radical treatment. The study will take progression free survival (PFS) as the main efficacy index, and plan to enroll about 62 patients with local recurrence of esophageal cancer after radical treatment. After fully informed and signed the informed consent, the subjects will enter the experimental stage after screening.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab combined with concurrent radiotherapy and chemotherapy

Timeline

• Start date: 2021-12-01
• Primary completion: 2023-10-01
• Completion: 2024-08-01
• First posted: 2020-05-18
• Last updated: 2022-02-03

Locations

1 site across 1 country: China